We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ABDX Abingdon Health Plc

0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Abingdon Health Plc LSE:ABDX London Ordinary Share GB00BLF79J41 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 10.75 10.50 11.00 10.75 10.75 10.75 305,811 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Chemicals & Chem Preps, Nec 4.05M -3.45M -0.0284 -3.79 13.08M
Abingdon Health Plc is listed in the Chemicals & Chem Preps sector of the London Stock Exchange with ticker ABDX. The last closing price for Abingdon Health was 10.75p. Over the last year, Abingdon Health shares have traded in a share price range of 6.75p to 14.25p.

Abingdon Health currently has 121,716,822 shares in issue. The market capitalisation of Abingdon Health is £13.08 million. Abingdon Health has a price to earnings ratio (PE ratio) of -3.79.

Abingdon Health Share Discussion Threads

Showing 1351 to 1369 of 1650 messages
Chat Pages: 66  65  64  63  62  61  60  59  58  57  56  55  Older
Allot of these diagnostic companies could have been transformed during the pandemic. That they are still in dispute with the DHSC as the pandemic eases is another black mark against boris. How much business was done at cheese and wine parties. Smug barstewards.
Dave Gruen
Sorry Dave but the covid testing market is in tatters........stop talking your book and get real. Hyping up this stuff now makes you look very stupid........

Nice buy for a Gruen
I am afraid I would agree that COVID stocks are dead in the water. Jeremy clarkson was right when he wrote in the times yesterday that it looks ok on the surface but underneath the reality is grim....
I was referring to the Innova antigen tests subject to recall in the US because of misleading accuracy claims. I’ve edited my post to make that clear.
@Columbarius....actually you are not correct. Acon for example, received FDA EU approval for their Flowflex antigen test, which is precisely the same one that the DHSC/UKHSA have been buying in the hundrefs of millions for the UK since February. aren't correct either. Why else is the UKHSA about to announce this week the results of its latest tender to buy 800mln more tests?
Covid stocks aren't about Covid. They are about testing. People now like to test themselves. It will be an enduring consequence of this pandemic that more of us will be testing ourselves more often for Covid, flu, RSV and a few other ailments rather than running out to a GP and waiting for results, and waiting, and waiting.
Stay short. Target 18.
The Company hasn't got a game changing client. Until it does, or the share price gets into the teens to allow a buyout, there is no upside here.

shallow pockets
Now is the time to buy, not to sell. Did anyone think we wouldn't trade under the placing price? A whoosh looks imminent.
david gruen
Re-read my post on 22nd December, when I asked those who were noisily talking their book (long) to quieten down. This stock is in a death spiral. Avacta was not even a good enough test to pass Porton Down, let alone be a UK or global product saviour for Abingdon. It was never going to be bought in sufficient volume amidst Chinese scale and price dominance. So today is another dose of reality for those longs. There is no UK product that Abingdon has on its books that requires scale up volume production. I can hear their equipment rattling around in a dormant factory. Until UK Gov supports UK lateral flow manufacturing as a strategically important industry to avoid dependence on China and having to compete amidst a crisis in a global market, Abingdon is in dire jeopardy. It needs to find a British test which works and which is supported by UK Gov . Stay short. Target 18p.
shallow pockets
I've sold out. Enough failures and delays. No-ones fault - just shows the difficulty of creating and selling new products. Seems the govt did the right thing in buying cheap Chinese products.
Just shows what a waste of space a CE mark is. It's like buying a Degree at Bradford market.
10 January 2022

Abingdon Health plc

("Abingdon" or "the Company")

Update on AffiDX(R) SARS-CoV-2 antigen lateral flow test

Technical transfer completed mid-December as planned

Sales of AffiDX(R) paused by Avacta following Omicron sensitivity analysis

York, U.K. 10 January 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, provides the following update on Avacta Group plc's ("Avacta") AffiDX(R) SARS-CoV-2 antigen lateral flow test:

Completion of Technical Transfer

Abingdon confirms that it completed the technical transfer of the AffiDX(R) SARS-CoV-2 antigen lateral flow test assay product as planned. Technical transfer is the process of taking a developed product and optimising all processes and elements for mass manufacture. The final technical transfer batches were shipped to Avacta in mid-December 2021 with the products adhering to defined specifications and passing all quality control procedures.

Sensitivity of AffiDX(R) SARS-CoV-2 antigen lateral flow test

Abingdon also notes the announcement from Avacta this morning in relation to their AffiDX(R) SARS-CoV-2 antigen lateral flow test, which highlights that the sensitivity of the test is reduced at lower viral loads when identifying the Omicron variant, compared to the test's sensitivity with previous variants. The Company understands this is a characteristic reported for other lateral flow tests already on the market.

The Company notes that Avacta's Affimer(R) reagent in the AffiDX(R) test detects the Omicron variant with the same sensitivity as the Delta variant, and that it is the performance of the antibody, which pairs with the Affimer(R) in the test, that has been affected by the additional Omicron mutations. The Company also notes that Avacta has independently taken the decision to pause sales of the AffiDX(R) antigen test whilst it replaces the antibody in the product to ensure that its performance with the Omicron variant matches the high performance with previous mutations.

Abingdon scientists will work with Avacta to accelerate the process of replacing the antibody in the current assay format, and complete the process of technology transfer with this new specification.

COVID-19 Antigen Testing Products

The Company has two projects in COVID-19 antigen testing. These two projects involve the scale-up and technical transfer to manufacture for the AffiDX(R) SARS-CoV-2 antigen lateral flow test and for the Vatic KnowNow(TM) rapid antigen test developed by Vatic Health Limited which uses a saliva sample. The process of technical transfer for the Vatic KnowNow(TM) rapid antigen test remains on track with completion anticipated during calendar Q1 2022. According to Vatic the KnowNow test mimics the means through which the virus interacts with the surface of a human cell in order to detect it. As a result, they expect that it will continue to identify the SARS-CoV-2 virus even in the face of further potential mutations in the future.

Abingdon also has a pipeline of other non-COVID-19 contract service opportunities that it will seek to bring through technical transfer and into manufacture in due course.

david gruen
How rapid tests changed the pandemic
"I'm serious when I say they have been the single most powerful tool in reducing transmission of the virus," says Irene Petersen, professor of epidemiology at University College London.

david gruen
Neale Hanvey MP Red heartFlag of ScotlandRaised fist
@JNHanvey Just asked @Jacob_Rees_Mogg for a debate to allow @10DowningStreet to set out in detail the support the UK government are giving to domestic diagnostics. More useless deflection.

Time for a level playing field.

Their position is indefensible.

david gruen
I had almost written off the sale of the AbC-19 antibody tests but maybe that was premature of me.

Covid: Vaccines for all every four to six months not needed, says expert

It is not affordable or sustainable to keep vaccinating everyone against Covid-19 on the planet regularly, a UK vaccine scientist says.

Prof Sir Andrew Pollard, who helped develop the Oxford-AstraZeneca vaccine, says the most at risk should be identified and prioritised instead.

Approval almost certainly going to be denied
Approvals will come today/tomorrow. I can feel it in my water.
david gruen
Delays in approval mean UK lateral flow kits don’t pass the red-tape test
Access using googles cache... if problems reading, select text only version

H ttp://

Chat Pages: 66  65  64  63  62  61  60  59  58  57  56  55  Older

Your Recent History

Delayed Upgrade Clock